AAIC 2024 | The accuracy of plasma tau217 biomarkers in detecting AD pathology

Gemma Salvadó, PhD, Lund University, Lund, Sweden, discusses studies evaluating plasma ptau217 and non-phosphorylated tau217 as biomarkers for assessing amyloid or tau pathology in cognitively impaired individuals. The findings revealed that these blood biomarkers are as accurate as cerebrospinal fluid (CSF) biomarkers, with an accuracy of 90% in detecting Alzheimer’s disease (AD) pathology. This reflects the potential value of blood biomarkers in clinical practice. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2024 in Philadelphia, PA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.